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Abstract
16S ribosomal RNA methylase-mediated high-level resistance to
4-,6-aminoglycosides has been reported in clinical isolates of
gram-negative bacilli from several countries. Three of 1534
(0.2%) isolates of Klebsiella pneumoniae and three of 734 (0.4%)
Proteus mirabilis isolates from a university hospital in Athens,
Greece, were positive for rmtB and highly resistant to all amino-
glycosides tested (MICs ‡256 mg/L). Two of the K. pneumoniae
rmtB-bearing isolates, were KPC-2 and OXA-10 producers and
the third was a DHA-1 producer. One of the P. mirabilis isolates
was a VIM-1 and OXA-10 producer and one was an OXA-10
producer. All rmtB-harbouring isolates were clonally unrelated.
None of the E. coli (n = 1398) and Enterobacter spp. (n = 414)
isolates were positive for armA, rmtA, rmtB, rmtC or rmtD.
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Methylation of 16S ribosomal RNA (rRNA) has recently
emerged as a new mechanism of resistance against aminogly-
cosides among gram-negative pathogens [1]. It confers
high-level resistance to all parenterally administered amino-
glycosides that are currently in clinical use, as well as
ACHN-490, a next-generation aminoglycoside, currently in
early clinical development [2]. Six distinct genes, rmtA, rmtB,
rmtC, rmtD, armA and npmA encoding their respective
enzymes (16S rRNA methylases) have been identiﬁed in clini-
cal and veterinary strains from various geographic areas,
including East Asia, Europe and the Americas, since 2003
[1,3,4]. Those genes are mostly located on transposons
within transferable plasmids, which provides them with the
potential to spread horizontally and may in part explain the
already worldwide distribution of this novel resistance mech-
anism [5–8]. Some of these organisms have been found to
co-produce extended-spectrum b-lactamases or carbapene-
mases, contributing to their multidrug-resistant phenotypes.
The aim of this study was to investigate the occurrence of
16S rRNA methylase genes in Enterobacteriaceae isolates
from a university hospital in Athens.
The computerized database of Infectious Diseases Research
Laboratory was retrospectively searched for Enterobacteria-
ceae strains isolated during a 2-year period (November 2007–
October 2009) from inpatients and outpatients of the Attikon
University General Hospital, Athens, Greece. Only one isolate
per patient was included in the study. Species identiﬁcation of
isolated bacteria and MIC determinations were performed
using an automated system (BD Phoenix automated microbiol-
ogy system; BD Diagnostic Systems, Sparks, MD, USA). Iso-
lates resistant to amikacin and gentamicin were tested further
for MIC determination to amikacin, gentamicin, tobramycin,
netilmicin, apramycin and neomycin (Sigma-Aldrich, St Louis,
MO, USA) with the agar dilution technique following the Clini-
cal and Laboratory Standards Institute (CLSI) guidelines [9].
Escherichia coli ATCC 25922 and Pseudomonas aeruginosa
ATCC 27853 were used as control strains. Results were inter-
preted in accordance with European Committee on Antimi-
crobial Susceptibility Testing criteria [10].
Isolates with MICs ‡256 mg/L to amikacin, gentamicin, tob-
ramycin and netilmicin, were examined for the presence of 16S
rRNA methylase genes by multiplex PCR [1]. Genomic ﬁnger-
printing was carried out by repetitive-element PCR (rep-PCR)
analysis using primers 5¢ III GCG CCG ICA TCA GGC 3¢, and
5¢ ACG TCT TAT CAG GCC TAC 3¢. b-Lactamases were
determined by isoelectric focusing and the presence of the
responsible genes was conﬁrmed by PCR [11,12]. Sequencing
of the PCR products was performed by MWG-THE Genomic
Company (Ebersberg, Germany). Conjugation experiments
were performed by the broth mating technique, with E. coli
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K12 strain RC85 R– (rifampicin-resistant; MIC >128 mg/L) as
the recipient. Transconjugants were selected on agar supple-
mented with rifampicin (128 mg/L) and gentamicin (20 mg/L).
Gram-negative isolates belonging to species: Klebsiella
pneumoniae (n = 1534), E. coli (n = 1398), Proteus mirabilis
(n = 734) and Enterobacter spp. (n = 414) were included in
the study. In K. pneumoniae the percentage of resistance to
amikacin and gentamicin was 48.2% and 8.1%, respectively,
whereas resistance to both aminoglycosides was 0.9%. In
E. coli amikacin was more active with 3.6% of the isolates
being resistant, whereas 15.1% were resistant to gentamicin
and only 0.4% of the isolates were resistant to both amino-
glycosides. In P. mirabilis 8.0%, 40.5% and 1.1% were resistant
to amikacin, gentamicin and both aminoglycosides, respec-
tively. Finally Enterobacter spp. isolates exhibited resistance
rates of 12.5% to amikacin, 8.5% to gentamicin and 1.0% to
both aminoglycosides, respectively.
A high percentage of resistance to amikacin among K. pneu-
moniae isolates and to gentamicin among P. mirabilis isolates
was observed. However, resistance to both amikacin and gen-
tamicin was less common (0.4–1.1%). Fourteen K. pneumoniae,
ﬁve E. coli, eight P. mirabilis and four Enterobacter spp. isolates
were further evaluated by agar dilution for high-level resistance
to amikacin, gentamicin, tobramycin and netilmicin. Among
them, three K. pneumoniae (0.2%) and three P. mirabilis isolates
(0.4%) were highly resistant to all four aminoglycosides (MICs
‡256 mg/L) whereas MICs to apramycin ranged from 4 to
16 mg/L (Table 1). All isolates were positive for rmtB.
All rmtB-bearing isolates were clonally unrelated. Two of
the K. pneumoniae isolates were KPC-2 and OXA-10 produc-
ers whereas the third one was a DHA-1 producer (Table 1).
One P. mirabilis isolate was a VIM-1 and OXA-10 producer,
one was an OXA-10 producer and one was not an ESBL
producer. None of the E. coli or Enterobacter spp. isolates
was positive for armA, rmtA, rmtB, rmtC or rmtD genes. Con-
jugation experiments were successful for one K. pneumoniae
(m2573A) and two P. mirabilis (m642C, m2651A) isolates.
RmtB was co-transferred with blaOXA-10 and blaTEM-1 in all
three cases. Additionally blaVIM-1 was co-transferred from
P. mirabilis m642C to the E. coli transconjugant.
This is the ﬁrst report on the occurrence of 16S rRNA
methylases in Enterobacteriaceae in Greece and the ﬁrst
report on the occurrence of rmtB in P. mirabilis in Europe.
We have found a low prevalence of rmtB (0.2% among
K. pneumoniae and 0.4% among P. mirabilis), lower than that
found in Turkey (0.7%) and France (1.3%) among ESBL-
producing Enterobacteriaceae and higher than that reported
in Belgium (0.12%) among Enterobacteriaceae consecutively
collected between 2000 and 2005 [13,14]. Currently, the
16S rRNA methylase seems to be more prevalent in Asia T
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than in Europe and the Americas [1]. RmtB was associated
with carbapenemase or acquired AmpC-type production and
OXA-10 in K. pneumoniae and P. mirabilis isolates. The spread
of extensively drug-resistant isolates co-producing a carbape-
nemase or an acquired AmpC, an ESBL and 16S rRNA meth-
ylases raises clinical concern and may become a major
therapeutic threat in the future. Furthermore, these ribo-
somal methylases may compromise the usefulness of ACHN-
490, a much anticipated novel aminoglycoside with potent
activity against a variety of gram-negative pathogens.
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